Vakil N, Go M F
University of Wisconsin Medical School, Department of Gastroenterology, Milwaukee, Wisconsin 77030, USA.
Curr Opin Gastroenterol. 2000 Jan;16(1):32-9. doi: 10.1097/00001574-200001000-00006.
Combination antimicrobial therapies for the effective eradication of Helicobacter pylori infection have been identified and are commercially available. Ongoing studies to improve eradication rates are based on modification of currently approved treatments. Management of H. pylori infection now focuses on which patients should be treated and, by extension, which should be tested, because all patients should have a positive test result for H. pylori before starting antimicrobial therapy. Peptic ulcer disease was believed to be caused by acid abnormalities until about two decades ago, when H. pylori was successfully cultured; the clinical records of an early proponent of an infectious cause of peptic ulcer disease were recently discovered. The role of H. pylori infection in gastroesophageal disease and in ulcer disease associated with nonsteroidal anti-inflammatory drugs have become intensely investigated topics. Consensus conferences among pediatric physicians are establishing practice guidelines for H. pylori management in children and adolescents.
已确定了用于有效根除幽门螺杆菌感染的联合抗菌疗法，并且这些疗法已在市场上有售。目前正在进行的提高根除率的研究是基于对当前已批准治疗方法的改进。幽门螺杆菌感染的管理现在侧重于哪些患者应接受治疗，进而哪些患者应接受检测，因为所有患者在开始抗菌治疗前幽门螺杆菌检测结果都应呈阳性。直到大约二十年前幽门螺杆菌成功培养出来之前，消化性溃疡病一直被认为是由胃酸异常引起的；最近发现了一位早期支持消化性溃疡病感染病因的医生的临床记录。幽门螺杆菌感染在胃食管疾病以及与非甾体抗炎药相关的溃疡病中的作用已成为深入研究的课题。儿科医生之间的共识会议正在制定儿童和青少年幽门螺杆菌管理的实践指南。
